PRQR today
$1.36+$0.10 (+7.94%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns up above $2.46
Key levels
Resistance$1.55
Resistance$1.45
Support$1.30
Support$1.20
Latest news & SEC filings
EarningsProQR Therapeutics posts smaller quarterly loss than expected, revenue tops forecast
NewsProQR schedules presentations on two pipeline candidates
All PRQR news →About ProQR Therapeutics
ProQR Therapeutics develops medicines that modify RNA, using a platform called Axiomer to direct naturally occurring enzymes to make targeted changes in genetic messages. Its programs address diseases of the liver and brain, including cholestatic disorders, Rett syndrome, fatty liver disease, and heart-related conditions. The company is based in the Netherlands and also has offices in Massachusetts, and it works with partners such as Eli Lilly and the Rett Syndrome Research Trust.
Based on the company's 20-F filed Mar 12, 2026.
Nasdaq · Healthcare
ProQR Therapeutics N.V. (PRQR)
What Is the Price Target for PRQR?
SEPT Low Target
$3.00
SEPT Mid Target
$7.00
SEPT High Target
$8.00
Analyst Consensus
$7.00
Is PRQR a Buy or Sell Right Now?
Thesis
- •Revenue growing -12.2% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PRQR.
Start Free Trial →Is PRQR Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$7.00
17
Moat Score
NONE
1/9
Piotroski Score
-5.1
Altman Z-Score
What Is Smart Money Doing with PRQR?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PRQR Growth Story
Revenue YoY
-12.2%
3yr Revenue CAGR
68.1%
EPS Growth YoY
-30.42%
FCF Growth YoY
-48.5%
Revenue Trend
STRONG
Dark Pool Trades for PRQR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PRQR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:01:48 | $1.30 | 2,000 | $$3K | SELL |
| 20:59:52 | $1.35 | 1,774 | $$2K | MIDPOINT |
| 20:59:45 | $1.35 | 1,300 | $$2K | SELL |
| 20:59:39 | $1.36 | 1,100 | $$1K | BUY |
| 20:59:17 | $1.35 | 1,100 | $$1K | SELL |
5 dark pool trades shown · $$10K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ProQR Therapeutics N.V. (PRQR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PRQR — frequently asked questions
What is PRQR stock price today?
ProQR Therapeutics N.V. (PRQR) is at $1.36, up 7.94% (+$0.10) at the Nov 12, 2026 close.
Why is PRQR stock moving today?
Latest PRQR news — Nov 12, 2026: ProQR Therapeutics posts smaller quarterly loss than expected, revenue tops forecast · Oct 29, 2026: ProQR schedules presentations on two pipeline candidates
What is the PRQR price target?
The average analyst price target for PRQR is $7.00, ranging from $3 to $8, based on 4 analysts. Latest: B of A Securities initiates on Aug 20, 2026.
What do analysts rate PRQR?
Analyst ratings for PRQR: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did PRQR beat earnings?
PRQR last reported on Aug 13, 2026: EPS -$0.10 vs -$0.13 expected — a beat of 23.3%.
Does PRQR pay a dividend?
PRQR does not currently pay a dividend.
How much debt does PRQR have?
ProQR Therapeutics N.V. reported $6M of debt and $108M of cash (Dec 31, 2025).
What are PRQR support and resistance levels?
Support: $1.30, $1.20, $1.08. Resistance: $1.45, $1.55, $1.70.
What are insiders doing with PRQR?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on PRQR?
Nov 12, 2026: ProQR Therapeutics posts smaller quarterly loss than expected, revenue tops forecast · Oct 29, 2026: ProQR schedules presentations on two pipeline candidates